Iridex Corp. (NASDAQ:IRIX) Chief Financial Officer Romeo R. Dizon has acquired 2,400 shares of the company's common stock, a transaction executed on June 8, 2026. The purchase was completed at a price of $1.12 per share, resulting in a total investment of $2,688. This acquisition takes place while the equity is trading in the vicinity of $1.11. Market analysts have established a price target of $2.75 for the stock, a level that suggests a potential upside of 148% from current trading levels.
Following this recent acquisition, Mr. Dizon's direct ownership position in Iridex stands at 133,325 shares of common stock. According to analysis from InvestingPro, the current valuation of IRIX may indicate that the stock is undervalued at these levels. The company currently maintains a Financial Health score rated as "Fair." Despite this assessment, Iridex has not generated profitability over the last twelve months, reporting an earnings per share (EPS) of -$0.19 for that period.
In related developments, Iridex Corporation released its financial results for the first quarter of 2026, presenting a mixed performance profile. The company reported an EPS of -$0.03 for the quarter. This figure surpassed the consensus analyst expectation of -$0.05, delivering a positive surprise of 40%. However, the company experienced a shortfall in revenue generation. Iridex recorded revenue of $11.8 million, which fell short of the anticipated $13.17 million, representing a miss of 10.4%. This revenue miss highlights challenges in meeting market expectations, although the EPS beat indicates effective cost management strategies were employed during the period.
These financial developments have generated interest among investors, a reaction reflected in the positive aftermarket trading activity observed for the stock. The company's future guidance has emerged as a focal point for investors, despite the current challenges related to revenue. Analyst firms have not yet provided updates regarding any changes in their ratings for IRIX following this earnings report. The financial community is expected to maintain close scrutiny on Iridex's upcoming performance and any strategic adjustments the company may implement.